[1] 王新昭, 左文述, 于志勇. 三阴性乳腺癌新的认识和研究进展[J]. 国际肿瘤学杂志, 2013, 40(11): 846-849. DOI: 10.3760/cma.j.issn.1673422X.2013.11.014.
[2] Shiu KK, Tan DS, ReisFilho JS. Development of therapeutic approaches to ′triple negative′ phenotype breast cancer[J]. Expert Opin Ther Targets, 2008, 12(9): 1123-1137. DOI: 10.1517/14728222.12.9.1123.
[3] Wang B, Wang X, Wang J, et al. Expression of Ki67and clinicopathological features in breast cancer[J]. Chin J Oncol, 2014, 36(4): 273-275.
[4] Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. Arch Pathol Lab Med, 2007, 131(1): 18-43. DOI: 10.1200/JCO.2006.09.2775.
[5] Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer[J]. Mol Oncol, 2011, 5(1): 5-23. DOI: 10.1016/j.molonc.2010.11.003.
[6] Rakha EA, ElSayed ME, Green AR, et al. Prognostic makers in triplenegative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
[7] Qin Q, Gao F, Jiang W, et al. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki67 in breast cancer[J]. Chin Med J, 2014, 127(18): 3272-3277.
[8] De Azambuja E, Cardoso F, De Castro G, et al. Ki67 as prognostic marker in early breast cancer: a metaanalysis of published studies involving 12,155 patients[J]. Br J Cancer, 2007, 96(10): 1504-1513. DOI: 10.1038/sj.bjc.6603756.
[9] Cleator S, Heller W, Coombes RC. Triplenegative breast cancer: therapeutic options[J]. Lancet Oncol, 2007, 8(3): 235-244. DOI: 10.1016/S14702045(07)700748.
[10] Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and Ecadherin in triplenegative breast cancer[J]. Med Oncol, 2012, 29(2): 526-533. DOI: 10.1007/s1203201199482.
[11] Engebraaten O, Vollan HK, BrresenDale AL. Triplenegative breast cancer and the need for new therapeutic targets[J]. Am J Pathol, 2013, 183(4): 1064-1074. DOI: 10.1016/j.ajpath.2013.05.033.
[12] Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triplenegative breast cancer: clinical significance and prognostic associations[J]. Cancers (Basel), 2014, 6(3): 1351-1362. DOI: 10.3390/cancers6031351.
[13] Li CY, Wang P, Zhang S, et al. Clinicopathological features and prognosis of triplenegative breast cancer[J]. Chin J Oncol, 2013, 35(6): 463-467. |